EW Q3 2025 Earnings — Edwards Lifesciences Corporation Revenue & Financial Results | Market Cap Arena

EWEdwards Lifesciences Corporation

$50B

Q3 2025 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$1.6B+14.7% YoY

Gross Profit

$1.2B77.9% margin

Operating Income

$425M27.4% margin

Net Income

$291M18.7% margin

EPS (Diluted)

$0.50

QoQ Revenue Growth

+1.4%

Cash Flow

Operating Cash Flow

$574M

Free Cash Flow

$516M

Stock-Based Comp.

$41M

Balance Sheet

Total Assets

$13.3B

Total Liabilities

$3.1B

Stockholders' Equity

$10.2B

Cash & Equivalents

$2.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.6B	$1.4B	+14.7%
Gross Profit	$1.2B	$1.1B	+10.8%
Operating Income	$425M	$351M	+21.2%
Net Income	$291M	$3.1B	-90.5%

Revenue Segments

Transcatheter Heart Valves

$1.1B74%

Surgical Heart Valve Therapy

$258M17%

Transcatheter Mitral And Tricuspid Therapies

$145M9%

Geographic Segments

UNITED STATES

$908M65%

Europe

$388M28%

JAPAN

$90M7%